Key result
Fidarestat prevents doxorubicin-induced troponin-I elevation in mice while boosting colon cancer cell death ~25%.
Why the study?
Does fidarestat increase doxorubicin sensitivity and reduce cardiotoxicity in colorectal cancer models?
Does fidarestat increase doxorubicin sensitivity and reduce cardiotoxicity in colorectal cancer models?
Fidarestat may serve as an effective adjuvant therapy to enhance doxorubicin efficacy against colorectal cancer while mitigating its cardiotoxic effects.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for fidarestat as doxorubicin adjuvant in colorectal cancer; leaves open clinical translation pending human trials.
Anthracycline drugs such as doxorubicin (DOX) and daunorubicin remain some of the most active wide-spectrum and cost-effective drugs in cancer therapy. However, colorectal cancer (CRC) cells are inherently resistant to anthracyclines which at higher doses cause cardiotoxicity. Our recent studies indicate that aldose reductase (AR) inhibitors such as fidarestat inhibit CRC growth in vitro and in vivo. Here, we show that treatment of CRC cells with fidarestat increases the efficacy of DOX-induced death in HT-29 and SW480 cells and in nude mice xenografts. AR inhibition also results in higher intracellular accumulation of DOX and decreases the expression of drug transporter proteins MDR1, MRP1, and ABCG2. Further, fidarestat also inhibits DOX-induced increase in troponin-I and various inflammatory markers in the serum and heart and restores cardiac function in mice. These results suggest that fidarestat could be used as adjuvant therapy to enhance DOX sensitivity of CRC cells and to reduce DOX-associated cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Sonowal et al. (2017) studied Colorectal cancer and doxorubicin-induced cardiotoxicity. Fidarestat and Doxorubicin vs. Doxorubicin alone was evaluated on Cell death, tumor volume, and serum troponin-I levels. Fidarestat increased doxorubicin-induced cell death in colon cancer cells by approximately 25% and prevented doxorubicin-induced increases in serum troponin-I in mouse models.
Synapse has enriched 10 related papers. Consider them for comparative context: